• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

FDA Approves Fabre-Kramer Pharmaceuticals Major Depressive Disorder Treatment


EXXUA has been approved for treatment.

Fabre-Kramer Pharmaceuticals announced that the FDA has approved its treatment of major depressive disorder in adults.

In a press release, the company wrote that Exxua is the first antidepressant to be approved with a novel mechanism of action and is able to selectively target the serotonin 1A receptor.

"Exxua represents an important milestone in the treatment of MDD, a serious and debilitating condition that affects millions of people worldwide," said Stephen Kramer, M.D., CEO of Fabre-Kramer in a press release. "There is value in providing prescribers and patients with a wide range of effective options for use in clinical practice. We are proud to bring this innovative therapy to patients who need a new option to manage their depression and improve their quality of life."

According to Fabre-Kramer, Exxua is expected to be available in pharmacies starting in early 2024.


(Sept. 28, 2023); Fabre-Kramer Pharmaceuticals; Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults; https://www.prnewswire.com/news-releases/fabre-kramer-pharmaceuticals-announces-fda-approval-of-exxua-the-first-and-only-oral-selective-5ht1a-receptor-agonist-for-the-treatment-of-major-depressive-disorder-in-adults-301941467.html

Related Videos
Related Content